Compare WKHS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | INTS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 12.4M |
| IPO Year | 2008 | 2021 |
| Metric | WKHS | INTS |
|---|---|---|
| Price | $3.29 | $4.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $21.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 271.1K | 25.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $763,173.00 | N/A |
| Revenue This Year | $89.23 | N/A |
| Revenue Next Year | $28.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.19 |
| 52 Week High | $11.80 | $8.06 |
| Indicator | WKHS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 35.05 |
| Support Level | $3.22 | $0.31 |
| Resistance Level | $3.60 | $8.06 |
| Average True Range (ATR) | 0.40 | 0.21 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 29.98 | 20.24 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.